Lilly looks eastward with generics deal

Eli Lilly ($LLY) is reportedly in early talks with Turkish generics maker Mustafa Nevzat Ilac Sanayii AS, also known as MN. The talks possibly concern a partnership or investment.

A union of the two would give Lilly access to the low-cost product manufacturing, local distribution and regulatory expertise MN has in place, reports the Wall Street Journal. Turkey also serves a gateway to Asia.

MN makes generic antibiotics and would enjoy an expansive Western distribution network.

The Indianapolis drug giant recently reaped the benefits of a tie-up with Boehringer Ingelheim in a disease--rather than geographic--market deal. The collaborators are targeting diabetes and last month earned European regulatory approved for linagliptin, one of several late-stage diabetes drugs in mid- and late-stage development.

- here's the story

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.